Gerardo Peccia

Our popular tender war gaming workshop is now our most sophisticated yet. Run with differing competitors, visibility, and shaping and value criteria - and maybe an AI competitor!

Paolo Correale

A comprehensive look at how to prepare for global loss of exclusivity, including all the activities that happen earlier in the product lifecycle, what is changing in managing the product lifecycle ahead of LoE, as well as late stage price forecasting and brief review of all the tools in NAVLIN to help prepare for LoE.

Andrew Hanhauser

Two part workshop, covering hands-on experience with the fully launched new Ask NAVLIN generative AI experience and a tour of new NAVLIN products such as IRP Express and Market Access KPIs.

Alan Crowther and Heather Rae Martin

US is the largest – and most difficult to understand – market. This workshop will provide a structured review that will help European P&MA teams understand how pricing works in the US market and better manage or collaborate with their US colleagues, value assets for the US market and more.

Reinhard Rychlik

Session covering some specific areas of Germany reimbursement, including the 200 million EUR innovation fund, ATMP handling, and ATMP reimbursement.

Invitation only forum for the NAVLIN Software team and leadership to have an interactive session to cover details of the product roadmap, organizational and process improvements

Invitation only forum for the NAVLIN Data team and leadership to have an interactive session to cover details of the product roadmap, organizational and process improvements

First evening complimentary reception dinner at Portofino in Basel

An update on NAVLIN Software and Data plans for the years ahead and how we plan to meet the mission of global launch and in-line management of all products price and market access challenges.

Carlos Moreira and PwC share their thoughts on the broad factors in global market dynamics that pressure margins and how firms are rising to the challenge of margin optimization.

The team will share the benchmarking results from what pharmaceutical companies are doing to run and improve their operational pricing operations.

Pedro Borga, Amicus Therapeutics Discussion of the challenges around price & market access specific to smaller pharmaceutical and biotech firms, with perspectives from Amicus and the NAVLIN Staff.

Review globally of major policy trends and shifts in most of the major markets around the global and what it means for price and market access.

Session reviewing a case study implementation of NAVLIN Software including key value drivers to capture, best practices for a successful implementation, and some lessons learned from other implementations.

This session focuses on reviewing NAVLIN's NPS and CSAT scores to highlight key insights and trends, emphasizing how deeply we value customer feedback and its crucial role in driving our product development and innovation efforts

Explore a case study approach applicable to Ophthalmology, Men & Women's Health, and other Non-Reimbursed pharmaceuticals for how to navigate the landscape for price increases.

RWE's use in assessments is much discussed, but is it having any impact on actual re-assessments that include RWE? A review of what is

Pricing and market access does not operate independent of overall commercial strategy. Explore a case study of how to successfully integrate

A review of news trends and where we are going with policy coverage.

A detailed discussion of the specific challenges and opportunities of Artificial Intelligence in Pricing & Market Access. What works? What is overhyped? One year's worth of research from EVERSANA uncovers what we believe works and what is misguided. Followed by a robust panel discussion.

A look at pricing incremental innovation in fixed-dose combinations in cardiovascular and the implications for incremental valuation in general around FDCs, reformulations, and other mature lifecycle approaches.

Deep dive with the "Ask NAVLIN" AI and exploration of generative AI uses with NAVLIN Data, and what directions this exciting technology is going next.

Despite the significant number of Orphan Drugs, for many rare diseases, there is still no licensed treatment available, which means patients are treated off-label, often with generics, leading to implications for HTA.

Case study showing the significant price and revenue impacts of pricing and manufacturing site collaboration, with a survey of price/manufacturing policy considerations and an empiricial analysis of pricing and manufacturing site impacts using NAVLIN Data and Policy sources.

Oncology is the largest area of R&D spend, new product approvals, and a significant portion of healthcare spend. Look at what the trends and implications are from a pricing and access perspective.

Gain critical global intelligence on the innovative and outcomes-based agreement space. The NAVLIN Data team provides an update on exciting new capabilities in tracking innovative, outcomes, and managed entry agreements globally and how NAVLIN Software is enhancing its MEA agreement support and how it is integrating with NAVLIN Data.

An Evening with the Innovators at Kunsthalle

Critical decisions are based on accurate price and market access during business development and in/out-licensing, Phase II & Phase III that significant financial impact. The team shares insights to getting P&MA in early asset work right.

An update on where policy is going with Net Price Transparency and how firms should think about pricing and what the impacts both if net price transparency increases (vis-a-vis news in Spain) and if confidential rebates (like Germany) grow.

A look at how P&MA is being incorporated into Trial Design work and what the potential impact is of successful P&MA work in shaping trial design.

Detailed discussion of how to set launch price corridors with advanced analytical methods and how NAVLIN can help with this exercise.

Payer tactics and strategy when negotiating drug pricing with combination oncology drugs.

What are the trends in achieving and benchmarking price and market access in launch and throughout the lifecycle, and what are some of the considerations and tools to help achieve that.

Lyfegen discusses trends in outcomes based agreement and provides an overview of their outcomes-based agreement adjudication platform and agreement database

How to measure in-line price management and market access performance? This session walks through the KPIs you need and the ways to benchmark your price and market access performance to make sure you achieve your P&MA goals during the peak product years.

Discussion of an approach for loss-of-exclusivity forecasting with a comparison of detailed forecasting model and high-level predictive models to have an understanding of the importance of detailed planning and approach.

Discussion of pricing for LMIC markets, with a short panel discussion on what equitable pricing really means

A case study in looking at predictive pricing and its application to making operational pricing decisions.

With a large number of biologic patent expirations, EVERSANA provides our annual update on tender trends in biosimilar pricing with what the implications are for biosimilar pricing in general, from impacts for originators and entrants what it means for pipelines and planning.

Review of the drug shortage analytic capabilities within NAVLIN Data and how it can be used to not only look at shortages, but impacts on pricing and how it can even impact new drug reimbursement assessments.

An update from both the latest version of NRDL as well as a look at the multi-year trends of China's VBC initiative and some upcoming initiatives to potentially make launch more attractive for new products in China.